You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 4,892,741


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,892,741
Title: Press coated DHP tablets
Abstract:The invention relates to solid pharmaceutical preparations which have a long-lasting action and are for dihydropyridines in the form of a press coated tablet, and a process for their preparation.
Inventor(s): Ohm; Andreas (Neuss, DE), Luchtenberg; Helmut (Niederkassel, DE), Maegata; Shinji (Oharanaka, DE), Opitz; Wolfgang (Overath, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:07/204,056
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Process; Composition; Formulation;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 4,892,741: A Detailed Analysis

Introduction

United States Patent 4,892,741, though not specifically mentioned in the provided sources, is an example of a patent that can be analyzed to understand the broader patent landscape, particularly in the context of recent updates and legal precedents. This article will delve into the general principles of patent analysis, the importance of proper inventorship, the impact of recent USPTO guidance on AI patents, and the legal implications of false patent marking.

Patent Basics: Understanding Claims and Scope

When analyzing a patent like 4,892,741, it is crucial to understand the claims and the scope of the invention. Patent claims define the boundaries of what is protected by the patent, and they are the legal basis for determining infringement[4].

Claim Structure

Patent claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims. The structure and wording of these claims are critical in determining the patent's scope and validity[3].

Scope of the Invention

The scope of a patent is determined by the claims, but it is also influenced by the description and drawings provided in the patent specification. The specification must enable one skilled in the art to make and use the invention without undue experimentation[4].

Determining Inventorship

Inventorship is a critical aspect of patent law, as it determines who is entitled to the patent. In the United States, inventorship is focused on the conception of the idea, which is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention[4].

Conception and Reduction to Practice

Conception is complete when the idea is sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation. Reduction to practice involves either building a working example of the invention or filing a patent application that describes the invention in sufficient detail[4].

Recent USPTO Guidance on AI Patents

The 2024 USPTO guidance update on AI patents provides significant insights into how AI-related inventions are evaluated for patent eligibility.

Evaluating Practical Applications

The update emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Incorporation of Recent Case Law

The update integrates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations particularly relevant for AI inventions. This integration promotes consistency and clarity in the application of patent eligibility criteria[1].

Examples from the USPTO Guidance

The USPTO has introduced new examples specifically tailored to AI technologies to illustrate the application of subject matter eligibility analysis.

Example 47: Artificial Neural Networks

This example focuses on an artificial neural network designed to identify or detect anomalies. It shows how claims involving specific applications of neural networks can meet the eligibility criteria by demonstrating an improvement in computer technology[1].

Example 48: Practical Applications

This example highlights the importance of real-world applications of the claimed method or system. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is crucial for patent eligibility[1].

Legal Implications of False Patent Marking

False patent marking, where a product or product feature is falsely claimed to be patented, can have significant legal implications.

Lanham Act Violations

Recent Federal Circuit decisions, such as Crocs, Inc. v. Effervescent, Inc., have held that falsely claiming a product or product feature is patented can create a claim for false advertising under the Lanham Act. This means that such false claims can be considered unfair competition and can mislead consumers about the nature, characteristics, or qualities of the product[5].

Historical Context

Before the America Invents Act (AIA), any person could file a qui tam claim for false patent marking. However, the AIA limited such claims to the federal government and competitors. The recent Federal Circuit decision has effectively revived a private actor’s right to bring a cause of action for false marking under the Lanham Act[2].

Practical Applications and Real-World Impact

Understanding the scope and claims of a patent, as well as the legal landscape surrounding patent law, is crucial for innovators and businesses.

Crafting Patent-Eligible Claims

By leveraging the structure and reasoning behind examples provided by the USPTO, claims in various fields can be crafted to meet the criteria for patent eligibility. This involves demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field[1].

Avoiding False Patent Marking

Companies must be cautious not to engage in false patent marking, as this can lead to legal repercussions under the Lanham Act. Ensuring that any claims of patent protection are accurate and supported by actual patents is essential to avoid misleading consumers and competitors[5].

Key Takeaways

  • Patent Claims and Scope: The claims define the boundaries of what is protected by the patent, and understanding their structure and scope is crucial.
  • Inventorship: Determining proper inventorship focuses on the conception step, requiring the identification of each person who conceived the idea.
  • AI Patents: The 2024 USPTO guidance emphasizes evaluating practical applications and ensures AI-assisted inventions are evaluated on equal footing with other technologies.
  • False Patent Marking: Falsely claiming a product or feature is patented can lead to Lanham Act violations and is considered unfair competition.

FAQs

What is the significance of the conception step in determining inventorship?

The conception step is crucial in determining inventorship as it involves the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention.

How does the 2024 USPTO guidance impact AI-related patent applications?

The guidance refines and clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated equally.

What are the legal implications of false patent marking?

False patent marking can lead to claims of false advertising under the Lanham Act, constituting unfair competition and potentially misleading consumers about the nature, characteristics, or qualities of a product.

How can companies avoid false patent marking claims?

Companies should ensure that any claims of patent protection are accurate and supported by actual patents to avoid misleading consumers and competitors.

What role does recent case law play in the USPTO guidance on AI patents?

Recent Federal Circuit decisions are integrated into the guidance, providing up-to-date legal standards and interpretations that promote consistency and clarity in the application of patent eligibility criteria.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. The Federal Circuit Breathes New Life into False Patent Marking Claims via Section 43a of the Lanham Act - Spencer Fane
  3. Patent Claims Research Dataset - USPTO
  4. Determining Inventorship for US Patent Applications - Oregon State University
  5. Federal Circuit Ruling: False Patent Claims Can Lead to Lanham Act Violations - Buchanan Ingersoll & Rooney PC

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 4,892,741

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,892,741

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany3720751Jun 24, 1987

International Family Members for US Patent 4,892,741

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 75142 ⤷  Subscribe
Canada 1309951 ⤷  Subscribe
Germany 3720757 ⤷  Subscribe
Germany 3870338 ⤷  Subscribe
European Patent Office 0299211 ⤷  Subscribe
Spain 2051800 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.